BiotechTube

Gardasil Vaccine

Pre-clinicalCompleted
0 watching 0 views this week💤 Quiet
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Sexual Transmission of Infection

Conditions

Sexual Transmission of Infection

Trial Timeline

Sep 1, 2012 → Dec 1, 2014

NCT ID
NCT01489527

About Gardasil Vaccine

Gardasil Vaccine is a pre-clinical stage product being developed by Merck for Sexual Transmission of Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT01489527. Target conditions include Sexual Transmission of Infection.

Hype Score Breakdown

Clinical
5
Activity
2
Company
10
Novelty
2
Community
1

Clinical Trials (3)

NCT IDPhaseStatus
NCT01446718Pre-clinicalCompleted
NCT01489527Pre-clinicalCompleted
NCT00727636Pre-clinicalCompleted

Competing Products

18 competing products in Sexual Transmission of Infection

See all competitors
ProductCompanyStageHype Score
DapoxetineJohnson & JohnsonPhase 3
77
sildenafilPfizerApproved
84
sildenafilPfizerPhase 2
51
CP-866,087 + CP-866,087 + CP-866,087 + PlaceboPfizerPhase 2
51
PF-00446687 + PlaceboPfizerPhase 2
51
BremelanotidePfizerPhase 2
51
Sildenafil 100 mg + PlaceboPfizerPhase 2
51
AlfuzosinSanofiApproved
84
AVANAFIL + placeboSanofiPhase 3
76
Levitra (Vardenafil, BAY38-9456) + PlaceboBayerApproved
82
Placebo + 0.5 mgTestosterone + 10 mg BuspironeBrain BiotechPhase 2
44
Placebo + Testosterone + Buspirone hydrochlorideBrain BiotechPhase 2
44
Placebo + Sildenafil + TestosteroneBrain BiotechPhase 2
44
tibolone + estradiol-norethisteroneOrganonPhase 3
72
Bremelanotide + PlaceboPalatin TechnologiesPhase 3
69
bremelanotidePalatin TechnologiesPhase 2
44
BremelanotidePalatin TechnologiesPhase 3
69
EVO100 + PlaceboEvofem BiosciencesPhase 3
69

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85